[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-346563-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-346563-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","patient-derived-complex-organoids-are-a-critical-tool-to-understand-and-explore-pediatric-malignant-brain-tumors","Patient-derived complex organoids are a critical tool to understand and explore pediatric malignant brain tumors","","Pediatric malignant brain tumors (PMBTs) remain among the most common and challenging cancers in children and adolescents, and current therapies often fail to achieve satisfactory outcomes. Key barriers include intrinsic and extrinsic resistance mechanisms, creating a pressing need for innovative treatments and accurate preclinical models. Organoid-based 3D technologies can reproduce tumor features and a brain-like microenvironment, enabling investigation of resistant cancer cells and evaluation of novel therapeutic strategies in precision medicine.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/patient-derived-complex-organoids-are-a-critical-tool-to-understand-and-explore-pediatric-malignant-brain-tumors/346563/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/patient-derived-complex-organoids-are-a-critical-tool-to-understand-and-explore-pediatric-malignant-brain-tumors/346563.png","ImageObject",300,407,{"name":42,"@type":43},"Olivia Brown","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-27","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",10,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why are pediatric malignant brain tumors difficult to treat?","Question",{"text":63,"@type":64},"They face intrinsic and extrinsic resistance mechanisms, and existing therapies often do not deliver satisfactory outcomes.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What is the purpose of patient-derived complex organoids in this review?",{"text":68,"@type":64},"To explain how cultured 3D systems such as organoids and tumoroids help model PMBT biology and support precision medicine and therapeutic testing.",{"name":70,"@type":61,"acceptedAnswer":71},"How do organoid-based 3D models improve preclinical study compared with 2D models?",{"text":72,"@type":64},"They better preserve native tumor heterogeneity and include interactions with the brain microenvironment, providing more faithful representations of tumor behavior.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},346563,1790417609,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":55,"slug":125},"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":127,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":33,"preview_urls":145},16904993612988,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Cancer and Metastasis Reviews (2026) 45:11 [https://doi.org/10.1007/s10555-026-10316-3](https://doi.org/10.1007/s10555-026-10316-3)  \nPatient‑derived complex organoids are a critical tool to understand and explore pediatric malignant brain tumors  \nMarlène Deschuyter1,2 · Sophie Martin1,2 · Chinar Salmanli1,2 · Clémence Hubsch1,2 · Audrey Vincent1,3,4 ·  \nSamuel Meignan1,4,5 · Alessandro Furlan1,4,5 · Erika Cosset6 · Hélène Burckel1,7,8 · Georges Noel1,7,8 · Michel Salzet1,9 · Marie Duhamel1,9 · Antonella Raffo‑Romero1,9 · Cedric Boura1,10 · Sophie Pinel1,10 · Andres Coca11 · Antony Joud12 · Mélodie Anne Karnoub13 · Pascal Chastagner1,10,14 · Sandra Raimbault1,15 · Hélène Sudour‑Bonnange1,15 · Vincent Flacher1,16 · Chloé Bernhard1 · Natacha Entz‑Werlé1,2,17  \nReceived: 26 September 2025 / Accepted: 27 January 2026 © The Author(s) 2026  \nAbstract  \nPediatric malignant brain tumors (PMBTs) remain among the most common and challenging cancers in children and adolescents, with current therapies often failing to deliver satisfactory outcomes. A major obstacle is their intrinsic and extrinsic resistance mechanisms, underscoring the urgent need for innovative therapeutic strategies and accurate preclinical modeling. Recent advances in organoid-based technologies offer promising tools to mimic PMBTs more faithfully in vitro. These threedimensional (3D) models can replicate key features of the tumor and its brain-like microenvironment, providing valuable platforms for studying resistant cancer cells and testing novel treatment approaches. This review discusses the relevance of cultured 3D systems, organoids and tumoroids, in pediatric neuro-oncology, emphasizing their role in precision medicine. These models have become essential for dissecting the complex biology and dynamic biological processes of all PMBTs, while bridging clinical challenges with experimental discoveries, ultimately enabling more effective and personalized treatments for young patients.  \nKeywords Pediatric · Brain tumors · 3D culture · Organoid · Cerebroid · Tumoroid · Microfluidic  \n1 Introduction  \nPediatric central nervous system (CNS) tumors encompass an heterogenous group, spanning brain and spinal cord locations and multiple histotypes, as defined by the 5th World Health Organization (WHO) classification of 2021 [1–3] . To decide appropriate therapies, based on the histomolecular refinements of this classification, pediatric malignant brain tumors (PMBT) are categorized into three main groups: embryonic tumors (such as medulloblastomas (MB) and atypical teratoid/rhabdoid tumors (ATRT)), gliomas (highand low-grades, respectively HGG and LGG) and ependymomas (EPN) [1–6]. Each pediatric CNS histotype is also molecularly subdivided into several categories that reflect prognosis and metastatic risks. The identification of driving mutation or fusions in pediatric brain cancers played a pivotal role in their comprehension and became a powerful diagnostic tool now routinely used for those patients [1–6] .  \nExtended author information available on the last page of the article  \nNevertheless, to understand these drivers, their impact on tumoral cell ontogeny, and their role in intrinsic resistance or as potential therapeutic targets (Fig. 1) [7, 8], robust preclinical multi-omics approaches are required to accurately decipher the malignant specificities from RNA to protein modifications. Beyond epigenomic and genomic features used to classify PMBTs, the brain microenvironment provides critical insights into their pathogenesis, informed by developmental programs, tumoral imprinting of the normal brain cells and local immunity [9–14] . For example, posterior fossa tumors, which constitute over half of all PMBTs, are in correlation with patients’ young age and the putative origin of malignant cells [15] . These histological and biological disparities reflect inherent intra-tumoral cellular heterogeneity and microenvironmental interaction, underscoring PMBTs as fundamenta","cbCaiapzm8XZXS4T","https://ap.wps.com/l/cbCaiapzm8XZXS4T","pdf",1540645,"English","# Abstract\n# Introduction","[{\"question\":\"Why are pediatric malignant brain tumors difficult to treat?\",\"answer\":\"They face intrinsic and extrinsic resistance mechanisms, and existing therapies often do not deliver satisfactory outcomes.\"},{\"question\":\"What is the purpose of patient-derived complex organoids in this review?\",\"answer\":\"To explain how cultured 3D systems such as organoids and tumoroids help model PMBT biology and support precision medicine and therapeutic testing.\"},{\"question\":\"How do organoid-based 3D models improve preclinical study compared with 2D models?\",\"answer\":\"They better preserve native tumor heterogeneity and include interactions with the brain microenvironment, providing more faithful representations of tumor behavior.\"}]","Patient-derived complex organoids are a critical tool to understand and explore pediatric malignant brain tumors | PDF",1790061987,48,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bda832c95adcc69294aabfb88693658a.webp",983,1305,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2a7fe49a2ba331e6a0f171a6fd17537a.webp",982,1304,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6c0dd67ba60c4f8d92f657986706d501.webp",981,1303,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0bb58c3983e8400b7e9e88daaef8777b.webp",980,1301]